Brief: Orexo Partner Trinity Health To Offer Vorvida, Deprexis To Patients
Sept 7 (Reuters) - Orexo AB ORX.ST :
* OREXO'S PARTNER TRINITY HEALTH TODAY ANNOUNCES THE AVAILABILITY OF VORVIDA® AND DEPREXIS®
TO
PATIENTS
* TRINITY HEALTH WILL NOW OFFER OREXO'S EVIDENCE-BASED DIGITAL THERAPIES VORVIDA® AND
DEPREXIS® TO
HELP PATIENTS MANAGE DEPRESSION AND EXCESSIVE DRINKING
Source text for Eikon: ID:nWkrblRyx6
Further company coverage: ORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens